02552 Hua Medicine

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial

SHANGHAI, China, June 18, 2020 (GLOBE NEWSWIRE) -- Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin. Dorzagliatin is a first-in-class glucokinase activator. The 52-week trial investigated the efficacy and safety of 75mg BID dorzagliatin in 463 patients with Type 2 diabetes, with an initial 24-week double blinded, placebo-controlled treatment, followed by an open label 28-week treatment. The primary efficacy and safety endpoints were evaluated at 24 weeks.

In November 2019, Hua Medicine announced the trial had achieved its primary efficacy and safety endpoints over the initial 24-week double blinded period.  For the 52-week treatment period, the efficacy and safety profiles were sustained based on the topline data analysis.   During the 28-week open-label period, patients initially receiving a placebo (i.e., the placebo group) were administered dorzagliatin for the first time.  Figure 1 below illustrates the efficacy (as measured by HbA1c reduction) for the two-cohort groups for the entire 52-week period. 

Figure 1 accompanying this announcement is available at 

HbA1c Reduction

 24 weeks52 weeksp-value*
Treatment Group (simple mean calculation)-1.15-1.11<0.001
Placebo Group (simple mean calculation)-0.58-1.27<0.001

*p<0.001 compared with baseline at 52 week

In the 28-week open label treatment period, dorzagliatin continued to exhibit a safe and well-tolerated clinical profile. A safety analysis based on study safety population demonstrated that dorzagliatin was well tolerated and had a good safety profile. The incidence of adverse events was similar between the dorzagliatin-treated and placebo groups. There was less than 1% hypoglycemia with blood glucose < 3 mmol/L during the 52-week treatment period. During the 28-week open-label treatment, patients also saw a continued reduction of insulin resistance (insulin resistance is the hallmark of Type 2 diabetes).

“We are incredibly proud of our accomplishment. The Hua Medicine team and our partners have worked closely together over the last decade to advance the development of dorzagliatin,” said Dr. Li Chen, CEO and founder of Hua Medicine. “With the successful completion of SEED, we become the first company to advance a glucokinase activator through clinical development. This is an incredible achievement for the Hua Medicine team, Chinese investigators, Hua’s partners and supporters, and most importantly, for Type 2 diabetes patients globally.” On Sunday, June 14th, 2020, Dr Chen presented more comprehensive data of the 24-week double blinded, placebo-controlled period of SEED study at the ADA 2020 80th Scientific Sessions.  In addition to reduced glucose levels, the data presented at the ADA indicated improved beta cell function for the dorzagliatin-treatment group (as measured by the clinically meaningful biomarker HOMA2-β).  In contrast, the placebo group experienced reduced beta cell function during the same period. Dr. Chen added: “Hua Medicine will continue its efforts to develop a potential disease modifying therapy to treat diabetes." 

SEED (Efficacy and Safety Evaluation of Dorzagliatin) study design

SEED is a randomized, double-blind, placebo-controlled Phase III study in 463 drug naïve type 2 diabetes patients. Patients are treated with twice-daily doses of dorzagliatin (75 mg) or placebo, randomized 2:1. The clinical study evaluated the efficacy and safety of dorzagliatin during 24 weeks of double-blinded treatment, followed by a subsequent 28-week open-label treatment period, for a total of 52 weeks. During the 28-week open-label period, both patient groups were treated with twice-daily doses of dorzagliatin (75 mg).  The trial was conducted in compliance with the guidelines of the Chinese Society of Endocrinology, which require physicians to educate patients and strictly enforce improved exercise and dietary control, as well as continuous self-monitoring, in treating Type 2 diabetes. The trial was conducted at 40 clinical sites across China led by Professor Dalong Zhu, President of the Chinese Diabetes Society.

About Dorzagliatin

Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 Diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 Diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.

About Hua Medicine

Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.

For more information
Hua Medicine
Website: 
Investors
Email:  
Media
Email:  
EN
18/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hua Medicine

 PRESS RELEASE

华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED...

华领医药成功完成Dorzagliatin单药治疗III期临床试验SEED研究(HMM0301) 中国,上海, June 18, 2020 (GLOBE NEWSWIRE) -- 华领医药(“公司”,香港联交所股份代号:2552.HK),一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司,今天宣布了dorzagliatin的首个III期临床试验SEED(也称为HMM0301)的结果。Dorzagliatin是一款葡萄糖激酶启动剂(GKA)首创新药。52周试验在463名2型糖尿病患者中开展,旨在研究患者接受一天两次dorzagliatin 75mg用药治疗的疗效和安全性,前24周为随机双盲、安慰剂对照治疗,用以评估dorzagliatin的主要疗效终点和安全性,后28周为开放性药物治疗。 2019年11月,华领医药宣布SEED研究在前24周双盲治疗期达到主要疗效和安全性终点。基于核心资料分析,52周治疗保持了其疗效和安全性。在为期28周的开放药物治疗期间,最初接受安慰剂的患者(即安慰剂组)首次接受dorzagliatin治疗。图1说明了整个52周期间,两个治疗组的关键疗效结果[通过糖化血红蛋白(HbA1c)的下降评估]。 HbA1c下降水平:  24 weeks52 weeksp-value*Treatment Group (simple mean...

 PRESS RELEASE

華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED...

華領醫藥成功完成Dorzagliatin單藥治療III期臨床試驗SEED研究(HMM0301) 中國,上海, June 18, 2020 (GLOBE NEWSWIRE) -- 華領醫藥(“公司”,香港聯交所股份代號:2552.HK),一家針對全球糖尿病患者尚未滿足的臨床需求研發全球原創新藥的生物技術公司,今天宣佈了dorzagliatin的首個III期臨床試驗SEED(也稱為HMM0301)的結果。Dorzagliatin是一款葡萄糖激酶啟動劑(GKA)首創新藥。52周試驗在463名2型糖尿病患者中開展,旨在研究患者接受一天兩次dorzagliatin 75mg用藥治療的療效和安全性,前24周為隨機雙盲、安慰劑對照治療,用以評估dorzagliatin的主要療效終點和安全性,後28周為開放性藥物治療。 2019年11月,華領醫藥宣佈SEED研究在前24周雙盲治療期達到主要療效和安全性終點。基於核心資料分析,52周治療保持了其療效和安全性。在為期28周的開放藥物治療期間,最初接受安慰劑的患者(即安慰劑組)首次接受dorzagliatin治療。圖1說明了整個52周期間,兩個治療組的關鍵療效結果[通過糖化血紅蛋白(HbA1c)的下降評估]。 HbA1c下降水準:  24 weeks52 weeksp-value*Treatment Group (simple mean...

 PRESS RELEASE

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s P...

Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin’s Phase III Monotherapy Trial SHANGHAI, China, June 18, 2020 (GLOBE NEWSWIRE) -- Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301), the first Phase III trial with dorzagliatin. Dorzagliatin is a first-in-class glucokinase activator. The 52-week trial investigated the efficacy and safety of 75mg BID dorzagliatin in 463 patients with Type 2 diabete...

 PRESS RELEASE

Hua Medicine’s Dorzagliatin Demonstrates Improvements in β-Cell Fun...

Hua Medicine’s Dorzagliatin Demonstrates Improvements in β-Cell Function in Data Presented at the American Diabetes Association’s 80th Scientific Sessions SHANGHAI, China, June 15, 2020 (GLOBE NEWSWIRE) -- Hua Medicine (the “Company”, Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced post-analysis results from dorzagliatin’s 24-week monotherapy trial SEED, (also known as HMM0301). The following findings from the SEED study were presented in oral and symposium presentations at the American Di...

 PRESS RELEASE

华领医药在美国糖尿病协会(ADA)第80届科学年会公å¸...

华领医药在美国糖尿病协会(ADA)第80届科学年会公布Dorzagliatin能够改善β细胞功能 中国上海, June 15, 2020 (GLOBE NEWSWIRE) -- 华领医药(「公司」,香港联交所股份代号:2552.HK),一家针对全球糖尿病患者尚未满足的临床需求研发全球原创新药的生物技术公司,今天公布了dorzagliatin单药治疗临床试验SEED(也称为HMM0301)的24周事后分析数据结果。 在美国糖尿病协会(ADA)第80届科学年会线上会议上,华领医药通过口头报告和专题讨论会对SEED研究进行了报告: 快速起效,糖化血糖蛋白(HbA1c)在用药4周后有效下降相比安慰剂对照组,治疗组β细胞功能明显改善相比安慰剂对照组,治疗组的餐后2小时血糖值显著下降安全性和耐受性好,低血糖发生率低,治疗组和安慰剂组的不良事件发生率相似24周持续有效良好的应答率 “Dorzagliatin的事后分析数据建立在此前24周顶线数据的积极结果基础上,”华领医药首席执行官兼首席科学官陈力博士说,“结果证明了dorzagliatin具有修复2型糖尿病患者血糖稳态的潜力,进一步支持了我们探索2型糖尿病基石治疗的努力。” 通过标记物测量,dorzagliatin显示出了对β细胞功能的明显改善数据表明,与安慰剂对照组相比,dorzagliatin治疗组的β细胞功能显著改善(通...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch